Stocks making the biggest moves before the bell: Oracle, Kohl’s, Coinbase, Southwest and more
Here’s a roundup of companies causing a stir in premarket trading:
— This IT giant saw its stocks rise by an impressive 13.3% following robust per-share earnings. Oracle revealed adjusted earnings per share of $1.41, surpassing the $1.38 consensus estimate identified by analysts at LSEG.
— The shoemaker suffered a sharp decrease in shares by more than 14% after its quarterly results fell short of expectations, leading to investor disappointment. On Holding’s fourth-quarter results revealed a loss of CHF0.05, falling below the anticipated CHF0.10 earnings per share. The company’s revenue of CHF447.1 million also missed the consensus estimate of CHF450.9 million.
— The retailer saw a 2.2% increase in shares post-reporting a triumphant earnings and revenue beat for Q4. The per-share earnings came in at $1.67, outpacing a consensus estimate of $1.28 according to LSEG. Its revenue was $5.71 billion, slightly higher than the expected $5.7 billion. Kohl’s also announced plans to introduce Babies R Us across approximately 200 stores this fall.
— Shares dipped 2.3% for this work management platform after it provided less than stellar full-year revenue guidance. Despite a commendable earnings report for Q4, Asana’s projected revenue of between $716-722 million missed the $725 million estimate from LSEG analysts.
— The crypto trading platform saw a 2.1% increase in shares following a more optimistic outlook by Raymond James, which upgraded the stock from underperform to market perform, highlighting the influence of exchange-traded funds on inflows.
— Shares for this airline depreciated by 7% following an announcement from the company about reevaluating its full-year 2024 guidance due to aircraft delivery delays from Boeing. The airline also shared weaker than anticipated first-quarter leisure bookings.
— The crypto company’s stocks surged 4.6% after B.Riley gave it a buy rating, citing the company’s diversified business model and access to low-cost power as key strengths.
— Following a positive clinical update, stocks for this biopharmaceutical rose by 7.1%. Both Wells Fargo and Oppenheimer upgraded their ratings for the company and increased their share price targets.
— A bitcoin developer, it saw its stocks leap by 6.2% aided by positive commentary from Wall Street analysts. As the firm maintains its buy rating, it also increased its price target to $1,810. TD Cowen keep its outperform rating and raised its target price to $1,560.
